PDCD1 and cancer: To date, the U.S. Food and Drug Administration (FDA) has approved three classes of ICIs targeting distinct immune checkpoints for cancer therapy, namely antibodies directed against cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1).